GSA Capital Partners LLP bought a new position in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 298,086 shares of the company's stock, valued at approximately $1,082,000. GSA Capital Partners LLP owned approximately 0.11% of Autolus Therapeutics at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also made changes to their positions in AUTL. ProShare Advisors LLC bought a new stake in shares of Autolus Therapeutics in the 2nd quarter worth approximately $43,000. Daiwa Securities Group Inc. raised its holdings in shares of Autolus Therapeutics by 2,659.7% in the 2nd quarter. Daiwa Securities Group Inc. now owns 15,868 shares of the company's stock worth $55,000 after purchasing an additional 15,293 shares in the last quarter. Herbst Group LLC acquired a new stake in shares of Autolus Therapeutics during the third quarter valued at approximately $91,000. Bayesian Capital Management LP purchased a new stake in shares of Autolus Therapeutics in the 1st quarter valued at approximately $100,000. Finally, B. Riley Wealth Advisors Inc. purchased a new stake in shares of Autolus Therapeutics in the 1st quarter valued at approximately $108,000. 72.83% of the stock is currently owned by institutional investors.
Shares of NASDAQ:AUTL opened at $3.08 on Friday. Autolus Therapeutics plc has a 52 week low of $2.94 and a 52 week high of $7.45. The company has a market cap of $819.56 million, a PE ratio of -2.55 and a beta of 2.04. The firm has a 50 day simple moving average of $3.91 and a 200 day simple moving average of $3.98.
Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.10). During the same period in the prior year, the firm posted ($0.26) EPS. On average, equities analysts predict that Autolus Therapeutics plc will post -0.84 earnings per share for the current year.
Several equities research analysts recently commented on the stock. Redburn Atlantic upgraded shares of Autolus Therapeutics from a "neutral" rating to a "buy" rating and set a $13.00 price target for the company in a research report on Friday. Needham & Company LLC restated a "buy" rating and issued a $9.00 price target on shares of Autolus Therapeutics in a research report on Monday, November 11th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $9.45.
View Our Latest Stock Analysis on AUTL
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Autolus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Autolus Therapeutics wasn't on the list.
While Autolus Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.